

Supporting Information © Wiley-VCH 2007

● Wilcy-VOI1 2007

69451 Weinheim, Germany

Switching the Interior Hydrophobicity of a Self-Assembled Spherical Complex through the Photoisomerization of Confined Azobenzene Chromophores

Takashi Murase, Sota Sato, and Makoto Fujita*

Department of Applied Chemistry, School of Engineering, The University of Tokyo, CREST, Japan Science and Technology Agency (JST), 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan

mfujita@appchem.t.u-tokyo.ac.jp

Contents

Procedure

• Synthesis and physical properties of ligands **1a**, **b** and complexes **2a**, **b** (including X-ray crystallographic analysis of **2a**).

Selected NMR and MS Spectra

- Self-assembly of spherical complexes 2a, b
 - · ¹H NMR/¹³C NMR/H-H COSY/HSQC spectra of **2a**, **b** (Figure S1–S9).
 - · CSI-MS spectra of 2a, b (Figure S10–S11).
- Diffusion-ordered NMR spectroscopy (DOSY) spectra
 - · DOSY spectrum of **2a** (Figure S12).
 - · DOSY spectrum of heterocomplex **2c** assembled from a mixture of ligand **1a** and ligand **1b** (4:20) (17% trans-azobenzene concentration) (Figure S13).

Photoisomerization (trans-to-cis)

- · UV-Vis spectra of ligand **1a** and complex **2a** before and after UV light irradiation (Figure S14).
- · ¹H NMR spectra of ligand **1a**, complex **2a**, and heterocomplex **2c** before and after UV light irradiation (Figure S15–S17).

Pyrene insertion into complex 2a.

- \cdot ¹H NMR spectra of pyrene in the absence/presence of complex **2a** in CD₃CN/D₂O = 1:3 (Figure S18).
- · Degree of upfield shift for pyrene in the various volume of CD_3CN-D_2O (Figure S19).

1-Pyrenecarboxaldehyde (3) insertion into complex 2a.

 \cdot ¹H NMR spectra of probe **3** in the absence/presence of complex **2a** in CD₃CN/D₂O = 1:1 (Figure S20).

General

NMR spectra were recorded on Bruker DRX-500 and AV-500 (500 MHz) spectrometer. All NMR spectral data were collected at 300 K and the chemical shift values reported here are with respect to an internal TMS standard for CDCl₃ and CD₃CN. MALDI-TOF (LD+, dithranol) mass spectra were recorded on Applied Biosystems Voyager DE-STR. CSI-MS (cold-spray ionization mass spectrometry) spectra were measured on a four-sector (BE/BE) tandem mass spectrometer (JMS-700C, JEOL) equipped with a CSI source. UV-Vis absorption spectra were recorded on a Shimadzu UV-3150 spectrometer. IR measurements were carried out as KBr pellets using a Varian Scimitar FTS-2000 instrument. The synchrotron X-ray diffraction study was carried out at 80.0 K (λ = 0.6890 Å) at PF-AR of the High Energy Accelerator Research Organization (KEK). The diffraction data were collected by Rigaku CrystalClear, and cell refinement and data reduction were performed using the HKL2000 program. Structural solution was performed using the SHELXS-97 (Sheldrick, 1990) program, and structural refinement was performed using the SHELXL-97 (Sheldrick, 1997) program.

Solvents and reagents were purchased form TCI CO., Ltd., WAKO Pure Chemical Industries Ltd., and Sigma-Aldrich Co. All the chemicals were of reagent grade and used without any further purification.

Ligand 1a and complex 2a were synthesized as follows:

- 3,5-Dibromo-4-hydroxybenzyl alcohol (**3**)^[1] and 4-(bromomethyl)azobenzene^[2] were prepared as described in the literatures.
- [1] A. Sudalai, G. S. K. Rao, Indian J. Chem., Sect. B 1989, 28, 858-859.
- [2] N. Iyi, T. Fujita, C. V. Yalamaggad, F. L. Arbeloa, *Appl. Clay Sci.* **2001**, *19*, 47–58.

1,3-Dibromo-5-hydroxymethyl-2-[[4-(phenylazo)phenyl]methoxy]benzene (4a). 3,5-Dibromo-4-hydroxybenzyl alcohol (3.04)10.8 mmol) and 4-(bromomethyl)azobenzene (2.76 g, 10.0 mmol) were dissolved in DMF (80 mL). Potassium carbonate (3.07 g, 22.2 mmol) was added, and the resulting mixture was stirred at 100 °C for 12 h. The solvent was evaporated, and the residue was redissolved in CHCl₃. The precipitates were filtered off and the filtrate was concentrated in vacuo. The crude product was purified by column chromatography on silica gel (ethyl acetate/hexane = 1:3) to give 4a as an orange powder (2.16 g, 4.53 mmol) in 45% yield: mp 124.2–125.2 °C. ¹H NMR (500 MHz, CDCl₃) δ : 7.97 (d, J = 8.4 Hz, 2H), 7.94 (d, J = 7.1 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.57 (s, 2H), 7.53 (t, J = 7.1 Hz, 2H), 7.48 (t, J = 7.1 Hz, 1H), 5.11 (s, 2H), 4.67 (d, J = 5.9 Hz, 2H), 1.75 (t, J = 5.9 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ : 152.7 (C), 152.6 (C), 152.0 (C), 139.8 (C), 139.1 (C), 131.1 (2CH), 129.1 (CH), 129.0 (CH), 123.0 (CH), 122.9 (CH), 118.6 (C), 74.1 (CH₂), 63.5 (CH₂). IR (KBr, cm⁻¹): 3327, 3060, 2883, 1702, 1546, 1468, 1454, 1399, 1377, 1267, 1258, 1155, 1056, 1015, 984, 836, 766, 739, 684, 547. MALDI-TOF MS m/z calcd for [M + H]⁺: 476.96; found 476.79. Anal. Calcd for $C_{20}H_{16}Br_2N_2O_2$: C, 50.45; H, 3.39; N, 5.88. Found: C, 50.18; H, 3.42; N, 5.68.

5-Hydroxymethyl-2-[4-(phenylazo)phenyl]methoxy-1,3-bis(4-pyridylethynyl)ben zene (5a). Tri-t-butylphosphine (0.90 mL, 0.30 mmol; 10% solution in hexane) and diisopropylamine (4.5 mL, 32 mmol) were added to a mixture of compound 4a (1.21 g, 2.53 mmol), 4-ethynylpyridine hydrochloride (1.08 g, 7.70 mmol), Pd(PhCN)₂Cl₂ (61.6 mg, 0.161 mmol), and copper(I) iodide (21.3 mg, 0.112 mmol) in degassed dioxane (18 mL). This mixture was stirred at 50 °C for 21 h under argon atmosphere. The reaction mixture was diluted with CHCl₃ (20 mL), filtrated, evaporated in vacuo, The CHCl₃ and redissolved in CHCl₃. layer was washed with ethylenediamine-containing water and brine, dried over anhydrous Na₂SO₄, filtrated, The crude product was purified by column and concentrated in vacuo. chromatography on silica gel (gradient elution from CHCl₃ to CHCl₃/MeOH = 30:1) to give **5a** as an orange powder (1.26 g, 2.42 mmol) in 96% yield: mp 172.5–173.5 °C. ¹H NMR (500 MHz, CDCl₃) δ : 8.60 (d, J = 5.5 Hz, 4H), 7.93 (d, J = 7.2 Hz, 2H), 7.91 (d, J = 8.3 Hz, 2H), 7.69 (d, J = 8.3 Hz, 2H), 7.59 (s, 2H), 7.53 (t, J = 7.2 Hz, 2H),7.49 (t, J = 7.2 Hz, 1H), 7.30 (d, J = 5.5 Hz, 4H), 5.43 (s, 2H), 4.72 (d, J = 5.8 Hz, 2H), 2.01 (br t, 1H). ¹³C NMR (125 MHz, CDCl₃) δ: 160.3 (C), 152.6 (C), 152.5 (C), 149.9 (CH), 139.7 (C), 137.1 (C), 133.0 (CH), 131.2 (CH), 131.0 (C), 129.2 (CH), 128.7 (CH), 125.4 (CH), 123.0 (CH), 122.9 (CH), 117.1 (C), 91.6 (C), 89.6 (C), 75.7 (CH₂), 63.8 (CH₂). IR (KBr, cm⁻¹): 3253, 3071, 3043, 2887, 2208, 1597, 1539, 1492, 1448, 1415, 1366, 1235, 1153, 1120, 1064, 1003, 968, 871, 819, 767, 685, 548, 498. MALDI-TOF MS m/z calcd for $[M + H]^{+}$: 521.20; found 521.00. Anal. Calcd for C₃₄H₂₄N₄O₂·0.5H₂O: C, 77.11; H, 4.76; N, 10.58. Found: C, 77.34; H, 4.85; N, 10.43.

Trimethyl[[[4-[4-(phenylazo)phenyl]methoxy-3,5-bis(4-pyridylethynyl)]phenyl]m ethyl]ammonium bromide (7a). Triphenylphosphine (561 mg, 2.14 mmol) and carbon tetrabromide (931 mg, 2.81 mmol) were added sequentially to a solution of compound **5** (500 mg, 0.960 mmol) in dry THF (45 ml) at room temperature under argon atmosphere. After stirring the mixture for 3 h, the quantitative formation of compound **6a** (not isolated) in the solution was confirmed by MALDI-TOF MS (*m/z* calcd for [M + H]⁺: 585.11; found 584.85). The above solution was treated with trimethylamine (22 ml, 94.6 mmol; 4.3 M solution in water) and stirred at room temperature for 21 h. The solvent was evaporated, and the residue was dissolved in CHCl₃. The CHCl₃ layer was washed with NaBr-containing water, dried over

anhydrous Na₂SO₄, filtrated, and concentrated in vavuo. The crude product was purified by column chromatography on silica gel (gradient elution from CH₃CN₃/H₂O $(10 \text{ wt\% NaBr}) = 50:1 \text{ to } CH_3CN_3/H_2O (10 \text{ wt\% NaBr}) = 10:1).$ The product was redissolved in CHCl₃, washed with water, dried over anhydrous Na₂SO₄, filtrated, and concentrated in vavuo to give 7a as an orange powder (580 mg, 0.902 mmol) in 94% yield: mp 182.5–183.5 °C. ¹H NMR (500 MHz, CD₃CN) δ : 8.60 (d, J = 6.0 Hz, 4H), 7.90 (d, J = 7.8 Hz, 2H), 7.85 (d, J = 8.2 Hz, 2H), 7.79 (s, 2H), 7.75 (d, J = 8.2 Hz, 2H), 7.62-7.55 (m, 3H), 7.41 (d, J = 6.0 Hz, 4H), 5.57 (s, 2H), 4.45 (s, 2H), 3.08 (s, 9H). ¹³C NMR (125 MHz, CD₃CN) δ: 163.6 (C), 153.6 (C), 153.5 (C), 151.0 (CH), 141.1 (C), 140.0 (CH), 132.6 (CH), 131.3 (C), 130.5 (CH), 130.4 (CH), 126.4 (CH), 125.2 (C), 123.8 (CH), 123.7 (CH), 118.8 (C), 93.3 (C), 89.3 (C), 76.9 (CH₂), 68.6 (CH₂), 53.6 (CH₃). IR (KBr, cm⁻¹): 3023, 2884, 2216, 1594, 1538, 1487, 1447, 1411, 1375, 1240, 1220, 1142, 1068, 990, 926, 880, 820, 768, 687, 546, 508. MALDI-TOF MS m/z calcd for $[M - Br^{-}]^{+}$: 562.26; found 562.04. Anal. Calcd for C₃₇H₃₂BrN₅O·2.5H₂O: C, 64.63; H, 5.42; N, 10.18. Found: C, 64.37; H, 5.54; N, 9.95.

Trimethyl[[[4-[4-(phenylazo)phenyl]methoxy-3,5-bis(4-pyridylethynyl)]phenyl]m ethyl]ammonium trifluoromethanesulfonate (1a). Compound 7a (94.6 mg, 0.147 mmol) and silver trifluoromethanesulfonate (37.9 mg, 0.147 mmol) were dissolved in a CH₃CN (8 mL). The resulting mixture was stirred at room temperature for 12 h under argon atmosphere. The reaction mixture was filtrated and concentrated in vacuo to give 1a as an orange powder (96.9 mg, 0.136 mmol) in 93% yield: mp 176.8–177.8 °C. ¹H NMR (500 MHz, CD₃CN) δ : 8.61 (d, J = 6.0 Hz, 4H), 7.90 (d, = 6.7 Hz, 2H, 7.89 (d, J = 8.4 Hz, 2H), 7.75 (s, 2H), 7.75 (d, J = 8.4 Hz, 2H),7.61-7.56 (m, 3H), 7.40 (d, J = 6.0 Hz, 4H), 5.58 (s, 2H), 4.38 (s, 2H), 3.05 (s, 9H). ¹³C NMR (125 MHz, CD₃CN) δ: 163.6 (C), 153.6 (C), 153.5 (C), 151.1 (CH), 141.1 (C), 139.9 (CH), 132.5 (CH), 131.2 (C), 130.5 (CH), 130.4 (CH), 126.3 (CH), 125.0 (C), 123.8 (CH), 123.7 (CH), 118.8 (C), 93.3 (C), 89.2 (C), 76.9 (CH₂), 68.8 (CH₂), 53.6 (CH₃). (The peak of CF₃SO₃⁻ is probably overlapped with that of solvent CD₃CN (δ: 118.4).) IR (KBr, cm⁻¹): 3040, 2883, 2217, 1595, 1539, 1489, 1440, 1412, 1370, 1259, 1225, 1160, 1031, 880, 821, 769, 689, 639, 547, 518. MALDI-TOF MS m/z calcd for $[M - CF_3SO_3^-]^+$: 562.26; found 561.83. Anal. Calcd for C₃₈H₃₂F₃N₅O₄S·H₂O: C, 62.54; H, 4.70; N, 9.60. Found: C, 62.80; H, 4.94; N, 9.44.

Complex 2a. Compound **1a** (12.6 mg, 17.7 μmol) was treated with Pd(CF₃SO₃)₂ solution (1.8 mL, 8.9 μmol; 4.9 mM solution in CD₃CN) at 50 °C for 4 h. The quantitative formation of complex **2a** was confirmed by ¹H NMR. The title compound was precipitated as an orange solid by adding diethyl ether to the solution. Isolated yield was 14.4 mg (0.658 μmol, 89%): mp > 160 °C (decomposed). ¹H NMR (500 MHz, CD₃CN) δ: 8.97 (d, J = 6.4 Hz, 96H), 7.80 (s, 48H), 7.77 (d, J = 7.3 Hz, 48H), 7.71 (d, J = 8.4 Hz, 48H), 7.54 (d, J = 8.4 Hz, 48H), 7.52 (d, J = 6.4 Hz, 96H), 7.51 (d, J = 7.3 Hz, 48H), 7.44 (t, J = 7.3 Hz, 24H), 5.39 (s, 48H), 4.39 (s, 48H), 3.02

(s, 216H). 13 C NMR (125 MHz, CD₃CN) δ : 164.0 (C), 153.4 (C), 153.3 (C), 152.2 (CH), 141.2 (CH), 140.3 (C), 135.9 (C), 132.4 (CH), 130.3 (C), 130.1 (CH), 129.6 (CH), 125.3 (C), 123.7 (CH), 123.6 (CH), 123.3 (C), 120.8 (C), 94.2 (C), 91.4 (C), 76.9 (CH₂), 68.2 (CH₂), 53.4 (CH₃). IR (KBr, cm⁻¹): 3055, 2883, 2216, 1765, 1613, 1496, 1444, 1371, 1256, 1161, 1065, 1030, 925, 879, 836, 769, 690, 639, 561, 517. CSI-MS (CF₃SO₃⁻) salt, CH₃CN): m/z 2294.1 [M-6(CF₃SO₃⁻)]⁶⁺, 1945.4 [M-7(CF₃SO₃⁻)]⁷⁺, 1683.1 [M-8(CF₃SO₃⁻)]⁸⁺, 1479.3 [M-9(CF₃SO₃⁻)]⁹⁺, 1316.6 [M-10(CF₃SO₃⁻)]¹⁰⁺, 1183.3 [M-11(CF₃SO₃⁻)]¹¹⁺, 1072.0 [M-12(CF₃SO₃⁻)]¹²⁺, 978.1 [M-13(CF₃SO₃⁻)]¹³⁺, 897.5 [M-14(CF₃SO₃⁻)]¹⁴⁺. Anal. Calcd for C₉₃₆H₇₆₈F₁₄₄N₁₂₀O₁₆₈S₄₈Pd₁₂·90H₂O: C, 47.72; H, 4.06; N, 7.13. Found: C, 47.50; H, 3.79; N, 6.85.

X-ray crystallographic analysis of 2a. Single crystals of complex **2a** were obtained by slow vapor diffusion of 1,4-dioxane into a CH₃CN solution of **2a** at 17 °C. The diffraction data were measured at 80.0 K [wavelength (λ) = 0.6890 Å] at Photon Factory–Advanced Ring for Pulse X-rays (PF-AR) of the High Energy Accelerator Research Organization (KEK). Space group $Fm\bar{3}m$, temperature (T) = 80.0 ± 0.1 K, a = 61.794 ± 0.007 Å, volume (V) = 235,959 ± 47 ų, atomic number (Z) = 4. Anisotropic least-squares refinement for the palladium atoms and isotropic refinement for the other atoms on 3231 independent merged reflections ($R_{\rm int}$ = 0.5704) converged at residual $wR_2(F^2)$ = 0.3816 for all data; residual $R_1(F)$ equals 0.2943 for 1149 observed data [$I > 2\sigma(I)$], and goodness of fit (GOF) equals 1.726. CCDC-637523 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Ligand 1b and complex 2b were synthesized as follows:

3,5-Dibromo-4-methoxybenzyl alcohol (**4b**) was prepared as described in the literatures.^[3]

[3] a) J. Boukouvalas, N. Lachance, M. Ouellet, M. Trudeau, *Tetrahedron Lett.* 1998, 39, 7665–7668; b) D. Zuev, J. A. Michne, H. Huang, B. R. Beno, D. Wu, Q. Gao, J. R. Torrente, C. Xu, C. M. Conway, J. E. Macor, G. M. Dubowchik, *Org. Lett.* 2005, 7, 2465–2468.

5-Hydroxymethyl-2-methoxy-1,3-bis(4-pyridylethynyl)benzene (5b).

Tri-t-butylphosphine (1.5 mL, 0.50 mmol; 10% solution in hexane) and diisopropylamine (5.0 mL, 36 mmol) were added to 3,5-dibromo-4-methoxybenzyl alcohol **4b** (1.22 g, 4.11 mmol), 4-ethynylpyridine hydrochloride (1.48 g, 10.6 mmol), Pd(PhCN)₂Cl₂ (94.7 mg, 0.247 mmol), and copper(I) iodide (31.8 mg, 0.167 mmol) in degassed dioxane (20 mL). This mixture was stirred at 50 °C for 27 h under argon atmosphere. The reaction mixture was diluted with ethyl acetate (20 mL), filtrated, evaporated in vacuo, and redissolved in ethyl acetate. The ethyl acetate layer was washed with ethylenediamine-containing water and brine, dried over anhydrous Na₂SO₄, filtrated, and concentrated in vacuo. The crude product was purified by column chromatography on silica gel (gradient elution from CHCl₃ to CHCl₃/MeOH = 30:1) to give **5b** as a grayish white powder (0.942 g, 2.77 mmol) in 67% yield: mp 150.0–151.0 °C. ¹H NMR (500 MHz, CDCl₃) δ : 8.62 (d, J = 5.0 Hz, 4H), 7.55 (s, 2H), 7.40 (d, J = 5.0 Hz, 4H), 4.69 (s, 2H), 4.15 (s, 3H), 2.54 (br s, 1H). ¹³C NMR (125 MHz, CDCl₂) δ: 161.6 (C), 149.8 (CH), 136.8 (C), 133.1 (CH), 131.2 (C), 125.5 (CH), 116.5 (C), 91.2 (C), 89.5 (C), 63.8 (CH₂), 61.7 (CH₃). IR (KBr, cm⁻¹): 3152, 2943, 2853, 2215, 1602, 1539, 1492, 1466, 1418, 1361,

1296, 1242, 1129, 1048, 1000, 963, 889, 819, 743, 661, 623, 547, 496. MALDI-TOF MS m/z calcd for $[M + H]^+$: 341.13; found 341.03. Anal. Calcd for $C_{22}H_{16}N_2O_2\cdot 0.2H_2O$: C, 76.82; H, 4.81; N, 8.14. Found: C, 77.20; H, 5.14; N, 7.79.

Trimethyl[[[4-methoxy-3,5-bis(4-pyridylethynyl)]phenyl]methyl]ammonium

bromide (7b). Triphenylphosphine (561 mg, 2.66 mmol) and carbon tetrabromide (1.19 g, 3.60 mmol) were added sequentially to a solution of compound **5b** (403 mg, 1.18 mmol) in dry THF (60 ml) at room temperature under argon atmosphere. After stirring the mixture for 3 h, trimethylamine (32 ml, 138 mmol; 4.3 M solution in water) was added and the resulting solution was stirred at room temperature for 20 h. The solvent was evaporated, and the residue was dissolved in CHCl₃. The product was precipitated from the CHCl₃ layer by vigorously shaking with water, filtrated, and dried in vavuo to give 7b as a bright yellow powder (413 mg, 0.893 mmol) in 76% yield: mp > 230 °C (decomposed). ¹H NMR (500 MHz, CDCl₃) δ : 8.62 (d, J =6.1 Hz, 4H), 7.85 (s, 2H), 7.39 (d, J = 6.1 Hz, 4H), 5.30 (s, 2H), 4.22 (s, 3H), 3.47 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ: 163.8 (C), 149.9 (CH), 138.7 (CH), 130.5 (C), 125.4 (CH), 123.0 (C), 117.3 (C), 92.9 (C), 88.0 (C), 67.0 (CH₂), 61.7 (CH₃), 52.9 (CH₃). IR (KBr, cm⁻¹): 3035, 3019, 2984, 2219, 1594, 1534, 1491, 1473, 1417, 1250, 1213, 1141, 993, 883, 822, 551, 510. MALDI-TOF MS m/z calcd for $[M - Br^-]^+$: 382.19; found 382.06. Anal. Calcd for C₂₅H₂₄BrN₃O·H₂O: C, 62.50; H, 5.46; N, 8.75. Found: C, 62.18; H, 5.47; N, 8.59.

Trimethyl[[[4-methoxy-3,5-bis(4-pyridylethynyl)]phenyl]methyl]ammonium

trifluoromethanesulfonate (1b). Compound **7b** (200 mg, 0.433 mmol) and silver trifluoromethanesulfonate (111 mg, 0.434 mmol) were dissolved in a CH₃CN (20 mL). The resulting mixture was stirred at room temperature for 10 h under argon atmosphere. The reaction mixture was filtrated and concentrated *in vacuo* to give **1b** as a light brown powder (207 mg, 0.389 mmol) in 90% yield: mp > 195 °C (decomposed). ¹H NMR (500 MHz, CD₃CN) δ: 8.64 (d, J = 5.9 Hz, 4H), 7.74 (s, 2H), 7.49 (d, J = 5.9 Hz, 4H), 4.39 (s, 2H), 4.24 (s, 3H), 3.06 (s, 9H). ¹³C NMR (125 MHz, CD₃CN) δ: 164.8 (C), 151.1 (CH), 140.0 (CH), 131.3 (C), 126.3 (CH), 124.5 (C), 118.0 (C), 93.1 (C), 89.0 (C), 68.8 (CH₂), 62.7 (CH₃), 53.5 (CH₃). (The peak of $CF_3SO_3^-$ is probably overlapped with that of solvent CD₃CN (δ: 118.4).) IR (KBr, cm⁻¹): 3037, 2983, 2218, 1596, 1538, 1491, 1474, 1421, 1277, 1260, 1226, 1159, 1031, 989, 881, 826, 757, 640, 574, 548, 518. MALDI-TOF MS m/z calcd for [M – $CF_3SO_3^-$]⁺: 382.19; found 381.99. Anal. Calcd for $C_{26}H_{24}F_3N_3O_4S$: C, 58.75; H, 4.55; N, 7.91. Found: C, 58.58; H, 4.81; N, 7.77.

Complex 2b. Compound **1b** (9.49 mg, 17.9 μ mol) was treated with Pd(CF₃SO₃)₂ solution (1.8 mL, 9.0 μ mol; 5.0 mM solution in CD₃CN) at 50 °C for 4 h. The quantitative formation of complex **2b** was confirmed by ¹H NMR. The title compound was precipitated as a pale yellow solid by adding diethyl ether to the

solution. Isolated yield was 9.46 mg (0.537 μmol, 72%): mp > 175 °C (decomposed).

¹H NMR (500 MHz, CD₃CN) δ: 9.07 (d, J = 6.5 Hz, 96H), 7.78 (s, 48H), 7.67 (d, J = 6.5 Hz, 96H), 4.36 (s, 48H), 4.20 (s, 72H), 3.00 (s, 216H).

¹³C NMR (125 MHz, CD₃CN) δ: 165.9 (C), 152.3 (CH), 141.3 (CH), 136.1 (C), 129.8 (CH), 124.7 (C), 116.9 (C), 94.3 (C), 91.3 (C), 68.4 (CH₂), 63.2 (CH₃), 53.4 (CH₃). IR (KBr, cm⁻¹): 3049, 2882, 2825, 2215, 1613, 1498, 1476, 1421, 1256, 1160, 1065, 1029, 988, 880, 837, 757, 638, 561, 517.

CSI-MS (CF₃SO₃⁻ salt, CH₃CN): m/z 2052.1 [M-8(CF₃SO₃⁻)]⁸⁺, 1807.7 [M-9(CF₃SO₃⁻)]⁹⁺, 1611.9 [M-10(CF₃SO₃⁻)]¹⁰⁺, 1452.2 [M-11(CF₃SO₃⁻)]¹¹⁺, 1318.5 [M-12(CF₃SO₃⁻)]¹²⁺, 1205.8 [M-13(CF₃SO₃⁻)]¹³⁺, 1108.8 [M-14(CF₃SO₃⁻)]¹⁴⁺, 1024.8 [M-15(CF₃SO₃⁻)]¹⁵⁺, 951.8 [M-16(CF₃SO₃⁻)]¹⁶⁺, 887.1 [M-17(CF₃SO₃⁻)]¹⁷⁺. Anal. Calcd for C₆₄₈H₅₇₆F₁₄₄N₇₂O₁₆₈S₄₈Pd₁₂·48H₂O: C, 42.12; H, 3.67; N, 5.46. Found: C, 41.93; H, 3.94; N, 5.23.

3.8.3 Selected NMR and MS Spectra




Figure S1. ¹H NMR spectrum of 2a.




Figure S2. ¹³C NMR spectrum of 2a.




Figure S3. H–H COSY spectrum of 2a.




Figure S4. Enlarged H–H COSY spectrum of 2a.




Figure S5. HSQC spectrum of 2a.




Figure S6. Enlarged HSQC spectrum of 2a.




Figure S7. ¹H NMR spectrum of 2b.




Figure S8. ¹³C NMR spectrum of 2b.




Figure S9. HSQC spectrum of 2b.




Figure S10. CSI-MS spectrum of **2a**. The decomposition of **2a** was observed, resulting in the appearance of ligand (L)-deficient peaks, $[2a-L]^{n+}$.




Figure S11. CSI-MS spectrum of 2b.

Diffusion-ordered NMR spectroscopy (DOSY) tells us diffusion coefficient (D) of a molecule at a given temperature in solution and is a powerful method to separate complex mixtures according to D values. The DOSY spectra (in CD₃CN, 300 K) of complex $\bf 2a$ and heterocomplex $\bf 2c$ showed only one band, respectively, which indicates the quantitative formation of these complexes.




Figure S12. DOSY spectrum of 2a.




Figure S13. DOSY spectrum of heterocomplex 2c (17% azobenzene concentration).

Photoisomerization (trans-to-cis)

<UV-Vis spectra>




Figure S14. UV-Vis spectra of a) ligand **1a** and b) complex **2a** before and after UV light irradiation. Ligand concentration of complex **2a** is the same as the concentration of ligand **1a**; $[1a] = 3.0 \times 10^{-5}$ M in CH₃CN.

<1H NMR spectra>

It is known that aromatic protons in cis-form azobenzene are upfield-shifted, compared to those in trans-form, because the bending structure of cis-form results in receiving a magnetic shielding effect from the counterpart. The shielding effect affects the surroundings of the azobenzene. Actually, upfield shifts of the benzyl protons adjacent to the azobenzene unit in ligand $\bf 1a$ (5.57 ppm) were observed upon UV light irradiation ($\Delta \delta = -0.16$ ppm) (Figure S15).




Figure S15. ¹H NMR spectra of ligand **1a** a) before and b) after UV light irradiation (500 MHz, CD₃CN, 300 K, TMS).

The ¹H NMR spectral changes of complex **2a** were complicated than those of ligand **1a** (Figure S16). After UV irradiation, the peak intensity of the benzyl protons adjacent to the trans-azobenzene units in complex **2a** (5.39 ppm) decreased and three new peaks (5.46, 5.31, and 5.27 ppm) appeared. When one of 24 trans-azobenzene units in complex **2a** is converted to cis-isomer, the spherical symmetry of the complex is disturbed, and thus the magnetic environments around trans-azobenzene units neighboring to and far from the cis-isomer are different. Considered that the benzyl protons adjacent to cis-azobenzene units are upfield-shifted, it can be identified that two peaks in downfield region (5.46 and 5.39 ppm) and the other two peaks in upfield region (5.31 and 5.27 ppm) are assigned to trans- and cis-azobenzene units in complex **2a**, respectively.




Figure S16. ¹H NMR spectra of complex **2a** a) before and b) after UV light irradiation (500 MHz, CD₃CN, 300 K, TMS).




Figure S17. ¹H NMR spectra of heterocomplex **2c** a) before and b) after UV light irradiation (500 MHz, CD₃CN, 300 K, TMS).

Pyrene insertion into complex 2a.




Figure S18. ¹H NMR spectra (aromatic region) of a) pyrene, b) complex **2a**, and c) pyrene in the presence of complex **2a** (500 MHz, CD₃CN/D₂O = 1:3, 300 K, TMS).




Figure S19. Degree of upfield shift for pyrene $(-\Delta\delta_{pyrene, H2})$ in the various volume ratio of CD₃CN-D₂O. Complex **2a** was stable up to 75% D₂O solution.

1-Pyrenecarboxaldehyde (3) insertion into complex 2a.




Figure S20. ¹H NMR spectra of a) guest **3**, b) complex **2a**, and c) guest **3** + complex **2a** (500 MHz, $CD_3CN/D_2O = 1:1$, 300 K, TMS).